Lisata acquires Marea and signs $225 million financing agreement

Lisata ($LSTA) Therapeutics acquired Marea Therapeutics in a stock-for-stock transaction and signed a concurrent agreement for approximately $225 million in gross private-placement proceeds. The financing involves non-voting convertible preferred shares and is expected to fund operations into 2028. The acquisition is complete, while the financing announcement describes an agreement rather than confirming that all proceeds have been received.

The expanded pipeline centers on MAR001/005 for severe hypertriglyceridemia and MAR002 for acromegaly. Lisata plans to use the funds to complete the ongoing Phase 2b triglyceride study and a Phase 2 acromegaly trial, with both expected to report topline results in the fourth quarter of 2027. The transaction broadens the company’s development focus; the experimental medicines still need clinical validation and regulatory approval.

Sources:

• Lisata — Marea transaction and financing, GlobeNewswire reprint